PAVS:NASDAQParanovus Entertainment Technology Ltd. Analysis
Data as of 2026-06-10 - not real-time
$0.86
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Paranovus Entertainment Technology Ltd. (PAVS) is trading at a deep discount to its book value, with a price‑to‑book ratio of roughly 0.02, indicating severe undervaluation despite a market cap of under $1 M. The technical landscape is bleak: the 14‑day RSI sits near the oversold threshold, the MACD histogram is marginally positive yet the MACD line remains below its signal, and the 30‑day volatility exceeds 90%, all pointing to a fragile price structure. Fundamental metrics reinforce the downside narrative – revenue is modest at $12.4 M, gross and operating margins are negative, EBITDA is a loss of nearly $0.5 M, and both ROE and ROA are firmly in negative territory, while cash flow is negative and the company carries a debt‑to‑equity ratio above 10, underscoring solvency concerns. Liquidity is thin, with daily volume eclipsing the tiny market cap, and the stock has endured a near‑total drawdown of roughly 100%, suggesting extreme downside risk.
The combination of a bearish trend direction, high beta (≈2.0), extreme price volatility, and a sector classification of Consumer Defensive (Packaged Foods) – a space where pricing power is limited – further amplifies the risk profile. Given the lack of any dividend history and a payout ratio of zero, dividend sustainability is non‑existent. In sum, the stock appears dramatically undervalued from a price‑to‑book perspective but is beset by fundamental weakness, acute price volatility, and heightened systematic risk, making it a high‑risk, low‑return proposition at present.
The combination of a bearish trend direction, high beta (≈2.0), extreme price volatility, and a sector classification of Consumer Defensive (Packaged Foods) – a space where pricing power is limited – further amplifies the risk profile. Given the lack of any dividend history and a payout ratio of zero, dividend sustainability is non‑existent. In sum, the stock appears dramatically undervalued from a price‑to‑book perspective but is beset by fundamental weakness, acute price volatility, and heightened systematic risk, making it a high‑risk, low‑return proposition at present.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- bearish technical indicators (RSI oversold, MACD bearish)
- extreme price volatility and near‑total drawdown
- negative earnings and cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- price remains deeply discounted to book
- potential for turnaround if cash burn is curbed
- still elevated sector and regulatory risk
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- persistent negative margins and ROE/ROA
- high beta and systematic market exposure
- lack of dividend or sustainable cash generation
Key Metrics & Analysis
Financial Health
Revenue Growth18033.40%
Profit Margin-54.84%
ROE-21.54%
ROA-3.13%
Debt/Equity10.83
P/B Ratio0.0
Op. Cash Flow$-1862427
Free Cash Flow$2.3M
Technical Analysis
TrendBearish
RSI32.6
Support$0.86
Resistance$26.69
MA 20$1.06
MA 50$1.34
MA 200$320.89
MACDBullish
VolumeIncreasing
Fear & Greed Index83.8
Valuation
Fair Value$81.06
GradeUndervalued
TypeValue
Risk Assessment
Beta1.96
Volatility93.53%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.